Half-Life of Benlysta Subcutaneous Injection
The terminal elimination half-life of Benlysta (belimumab) after subcutaneous injection is 18.3 days in adults. 1
Pharmacokinetic Parameters
Based on FDA-approved drug labeling data from population pharmacokinetic analysis of 661 subjects receiving subcutaneous belimumab 200 mg once weekly 1:
- Terminal half-life (t½): 18.3 days
- Distribution half-life: 1.1 days
- Time to maximum concentration (Tmax): 2.6 days at steady state
- Bioavailability: Approximately 74% (compared to intravenous administration)
Comparison with Intravenous Administration
The subcutaneous formulation has a comparable terminal half-life to intravenous administration (19.4 days for IV vs 18.3 days for SC) 1. This similarity in elimination half-life between routes supports the once-weekly subcutaneous dosing regimen, which maintains steady-state concentrations with minimal fluctuations (Cmin 97 mcg/mL vs Cavg 104 mcg/mL).
Clinical Context
Research data from Japanese healthy volunteers corroborates these findings, reporting a geometric mean terminal half-life of 15.9 days after subcutaneous administration and 17.7 days after intravenous administration 2. The slight variation from FDA labeling data falls within expected intersubject variability and confirms the consistency of belimumab pharmacokinetics across populations.
Important caveat: In patients with lupus nephritis and significant proteinuria, belimumab clearance may be initially increased, potentially affecting exposure levels. However, as proteinuria improves with treatment (≤1 g/g), clearance normalizes to levels similar to those in SLE patients without nephritis 1. Despite this, no dose adjustment is recommended even in patients with high proteinuria.
The approximately 18-day half-life supports the weekly subcutaneous dosing schedule and explains why steady-state concentrations are achieved by Week 2 of dosing when using the 400 mg loading dose regimen for lupus nephritis 1.